Needham & Company LLC Lowers Merit Medical Systems (NASDAQ:MMSI) Price Target to $90.00

Merit Medical Systems (NASDAQ:MMSI) had its price target reduced by analysts at Needham & Company LLC from $101.00 to $90.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. Needham & Company LLC’s price objective suggests a potential upside of 32.00% from the stock’s current price.

A number of other equities analysts have also commented on MMSI. Canaccord Genuity Group dropped their price target on Merit Medical Systems from $99.00 to $90.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Piper Sandler dropped their price target on Merit Medical Systems from $106.00 to $96.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Wells Fargo & Company lowered Merit Medical Systems from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $95.00 to $78.00 in a research note on Thursday, February 26th. Citigroup reaffirmed an “outperform” rating on shares of Merit Medical Systems in a research note on Monday, April 20th. Finally, Barrington Research lowered their price objective on Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating for the company in a research note on Monday, April 20th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Merit Medical Systems has an average rating of “Moderate Buy” and a consensus price target of $98.33.

Merit Medical Systems Stock Performance

NASDAQ MMSI opened at $68.18 on Friday. The firm has a market cap of $4.07 billion, a price-to-earnings ratio of 32.16, a price-to-earnings-growth ratio of 1.83 and a beta of 0.64. The company has a quick ratio of 2.95, a current ratio of 4.34 and a debt-to-equity ratio of 0.46. The business has a 50-day moving average price of $70.68 and a 200-day moving average price of $79.78. Merit Medical Systems has a twelve month low of $63.78 and a twelve month high of $100.19.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings data on Tuesday, February 24th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.08. The firm had revenue of $393.94 million during the quarter, compared to analyst estimates of $390.77 million. Merit Medical Systems had a return on equity of 13.82% and a net margin of 8.48%.The business’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.93 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, equities research analysts predict that Merit Medical Systems will post 3.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Merit Medical Systems

Several hedge funds and other institutional investors have recently modified their holdings of MMSI. Tudor Investment Corp ET AL purchased a new stake in shares of Merit Medical Systems in the third quarter worth approximately $2,913,050,000. Wellington Management Group LLP raised its holdings in shares of Merit Medical Systems by 377.7% in the third quarter. Wellington Management Group LLP now owns 1,240,509 shares of the medical instruments supplier’s stock worth $103,248,000 after buying an additional 980,823 shares during the period. Norges Bank purchased a new stake in shares of Merit Medical Systems in the fourth quarter worth approximately $75,957,000. Thrivent Financial for Lutherans raised its holdings in shares of Merit Medical Systems by 250.5% in the third quarter. Thrivent Financial for Lutherans now owns 750,066 shares of the medical instruments supplier’s stock worth $62,428,000 after buying an additional 536,072 shares during the period. Finally, Iron Triangle Partners LP purchased a new stake in shares of Merit Medical Systems in the fourth quarter worth approximately $33,992,000. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q1 press release — Merit reported $381.9M revenue (+7% YoY), non‑GAAP EPS $0.94 (beat), GAAP EPS $0.68, non‑GAAP operating margin improved and free cash flow rose 26%. Management reorganized revenue reporting into Foundational and Therapeutic categories and highlighted margin and cash‑flow strength. Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance
• Positive Sentiment: Guidance raise — Merit updated FY2026 EPS guidance to $4.010–$4.150 vs. prior consensus ~3.93 and reiterated roughly $1.6B revenue, signaling management confidence in the year and providing a clear upside to street estimates. Merit Medical Tops Q1 Forecasts, Raises 2026 Outlook
• Positive Sentiment: Acquisition and divestiture activity — Merit acquired View Point Medical for $140M (adds OneMark imaging/markers) and sold DualCap® assets for $28M; the deals expand therapeutic offerings while monetizing non‑core assets. These M&A moves support growth and were cited by management on the call. Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance
• Positive Sentiment: Analyst/coverage notes — Multiple outlets (MarketBeat/Yahoo/Zacks) flagged that Merit beat revenue and EPS estimates for Q1, reinforcing the upside narrative and likely contributing to buying interest. Merit Medical Systems’s (NASDAQ:MMSI) Q1 CY2026: Beats On Revenue
• Neutral Sentiment: Detailed call commentary — The Q1 earnings call transcript provides color on procedure volumes, product adoption and the impact of the new reporting segmentation; useful for modeling but no new material surprises beyond the release. Merit Medical Systems, Inc. (MMSI) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Earnings snapshots — Outlets summarized beats (revenue and EPS), margin expansion and cash‑flow improvement; these recaps help confirm results but add little incremental info. Merit Medical: Q1 Earnings Snapshot
• Neutral Sentiment: Zacks recap — Reports Q1 EPS $0.94 vs Zacks $0.84 estimate (beat) and notes YoY EPS growth; useful confirmation for investors tracking consensus beats. Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates
• Neutral Sentiment: MarketBeat/Market data — Post‑release summaries and links to call materials and slides are available for deeper review; nothing contradictory to the company release. Merit Medical Systems Q1 report and call materials

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.